Obsidian raises $160.5m to advance TIL cell therapy programme
04 Apr 2024
Cell TherapyPhase 1ImmunotherapyClinical ResultGene Therapy
Preview
Source: Pharmaceutical Technology
TIL therapy uses naturally occurring immune cells that detect and attack cancer cells. Image credit: Shutterstock/Christoph Burgstedt.
Preview
Source: Pharmaceutical Technology
Obsidian Therapeutics has raised $160.5m in a Series C financing round, with plans for the funds to be injected into the biotech’s tumour-infiltrating lymphocyte (TIL) cell therapy programme.
Obsidian, already backed by Bristol Myers Squibb (BMS), added Novo Nordisk Foundation’s investment arm Novo Holdings to its arsenal of investors in this latest round. US investment firm Wellington Management led the oversubscribed Series C. The US biotech previously raised $115m in a Series B round in 2021.
Obsidian’s lead asset is OBX-115, which is part of its TIL programme. OBX-115 is a TIL cell therapy – which expands and enhances the patient’s own immune cells extracted from around and within the tumour itself. Unlike the emerging chimeric antigen receptor (CAR) T cell therapies, TILs already have multiple tumour target recognition.
The T cell immunotherapy is in a Phase I clinical trial for the treatment of melanoma and a Phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC).
In the melanoma trial (NCT05470283), which is being sponsored by the MD Anderson Cancer CentreCancer Centre, OBX-115 is being administered in combination with the diuretic acetazolamide. Data from the study will inform dose levels for a Phase II trial. The company reported an objective response rate of 50% and a complete response rate of 33% in topline data released in December 2023.
See Also:
Preview
Source: Pharmaceutical Technology
Pluri launches manufacturing division as cell therapy pipeline progresses
Preview
Source: Pharmaceutical Technology
The NSCLC trial (NCT06060613) is investigating OBX-115 as a monotherapy, with endpoints assessing the drug’s safety and efficacy in treating advanced solid tumours.
Obsidian said the Series C proceeds will go towards clinical trial activities and manufacturing scale-up with a view to conducting pivotal trials.
Obsidian has engineered OXB-115 such that it produces the membrane-bound interleukin 15 (IL-15). Interleukin-2 (IL-2) co-administration is usually needed with traditional TIL cell therapies to act as an immunostimulatory agent. Obsidian states that the membrane-bound IL-15 could widen patient access by reducing potential toxicities associated with high-dose IL-2.
Last month, Iovance Biotherapeutics’ Amtagvi (lifileucel) became the first TIL cell therapy to get regulatory backing in the US, winning a US Food and Drug Administration (FDA) accelerated approval. Obsidian’s OBX-115 will face competition from Iovance, with Amtagvi indicated for the treatment of metastatic or unresectable melanomametastatic or unresectable melanoma.
Iovance has priced its immunotherapy at $515,000 in a market where there are currently no other FDA-approved cell therapies for the treatment of solid tumours. Amtagvi is forecast to generate sales of $846m by 2029, according to GlobalData’s Pharma Intelligence Centre.
GlobalData is the parent company of Pharmaceutical Technology.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.